Matos Marcos Almeida, Tannuri Uenis, Guarniero Roberto
Department of Orthopedics and Traumatology, Bahian School of Medicine and Public Health, Itapuã, Salvador-Bahia, Brazil.
J Orthop Traumatol. 2010 Mar;11(1):7-12. doi: 10.1007/s10195-010-0083-1. Epub 2010 Feb 19.
Bisphosphonates have become the treatment of choice for a variety of bone diseases in which excessive osteoclastic activity is an important pathologic feature. However, inhibition of osteoclastic activity could lead to inhibition of remodeling during bone healing or repair. The objective of this study is to investigate the effect of zoledronate (the most potent bisphosphonate) in the biological process of bone healing.
Thirty immature male rabbits were divided into two groups (control and experimental) of 15 animals each. Both groups were submitted to fibular osteotomy. Only in the experimental group a single dose of zoledronate was administered. After 1, 2, and 4 weeks, animals of both groups were euthanized and the osteotomy site was histomorphometrically evaluated. The associated parameters analyzed were tissue volume (TV), fractional trabecular bone volume (BV/TV), fractional woven bone volume (WoV/TV), fractional periosteal fibrous volume (FbV/TV), and medullary fibrous volume (MaV/TV).
The first week of healing was characterized by small callus area (experimental group) and less periosteal fibrosis. The second week was characterized by a large quantity of woven bone and marked decrease in periosteal fibrosis in the two groups. In the control group there was also a significant increase in trabecular bone. The fourth week was characterized by increased amount of woven bone and trabecular bone in the experimental group; there was increased medullary fibrosis in the two groups, while there continued to be significantly less periosteal fibrosis in the experimental group.
Zoledronate does not prevent bone healing. However, the effect of zoledronate was characterized by accentuated stimulation of primary bone production and probably inhibition of remodeling, leading to retention of trabecular bone.
双膦酸盐已成为多种骨疾病的首选治疗药物,在这些疾病中破骨细胞活性过高是一个重要的病理特征。然而,抑制破骨细胞活性可能会导致骨愈合或修复过程中的重塑受到抑制。本研究的目的是探讨唑来膦酸(最有效的双膦酸盐)在骨愈合生物学过程中的作用。
将30只未成年雄性兔子分为两组(对照组和实验组),每组15只。两组均进行腓骨截骨术。仅在实验组给予单剂量的唑来膦酸。在1周、2周和4周后,对两组动物实施安乐死,并对截骨部位进行组织形态计量学评估。分析的相关参数包括组织体积(TV)、骨小梁体积分数(BV/TV)、编织骨体积分数(WoV/TV)、骨膜纤维体积分数(FbV/TV)和骨髓纤维体积(MaV/TV)。
愈合的第一周,实验组骨痂面积小且骨膜纤维化较少。第二周,两组均以大量编织骨和骨膜纤维化明显减少为特征。对照组的骨小梁也有显著增加。第四周,实验组的编织骨和骨小梁数量增加;两组的骨髓纤维化均增加,而实验组的骨膜纤维化仍然明显较少。
唑来膦酸并不妨碍骨愈合。然而,唑来膦酸的作用表现为对初级骨生成的明显刺激,可能还有对重塑的抑制,导致骨小梁保留。